{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-291800","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.441099+00:00","generated_at":"2026-06-07T15:40:52.434466+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcellx anito-cel Phase 1 shows 100% ORR, 76% CR; median PFS 28 months at 26.5 mo follow-up","bullets":["100% ORR (38/38) with 76% achieving CR/sCR; median PFS estimated at 28 months with 26.5 mo median follow-up.","Safety: no grade ≥3 CRS, one grade 3 ICANS; no delayed neurotoxicity or parkinsonian symptoms reported.","All 38 patients were triple-refractory; 68% penta-refractory; 63% had ≥1 high-risk clinical feature.","Upcoming oral presentation at ASH on Dec 11; company webcast with expert panel same day."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-291800","json":"https://secwatch.observer/filing/0001193125-23-291800.json","markdown":"https://secwatch.observer/filing/0001193125-23-291800.md","text":"https://secwatch.observer/filing/0001193125-23-291800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523291800/0001193125-23-291800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312523291800/d626117d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:40:52.434466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}